Provided by Tiger Trade Technology Pte. Ltd.

Acumen Pharmaceuticals, Inc.

2.89
+0.10003.58%
Pre-market: 2.920.0300+1.04%08:11 EDT
Volume:359.31K
Turnover:1.00M
Market Cap:208.69M
PE:-1.77
High:2.90
Open:2.77
Low:2.69
Close:2.79
52wk High:3.60
52wk Low:1.21
Shares:72.21M
Float Shares:37.05M
Volume Ratio:0.94
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6370
EPS(LYR):-2.0035
ROE:-120.50%
ROA:-45.77%
PB:3.64
PE(LYR):-1.44

Loading ...

Acumen Pharmaceuticals FY2025 EPS Loss Of $2.00 Vs. Loss Of $1.71 YoY, Cash, Cash Equivalents And Marketable Securities Of $116.9M With Cash Runway Into Early 2027

Benzinga Earnings
·
Mar 26

Acumen FY2025 net loss widens 18.57% to $121 million; operating loss climbs 8.62% to $124 million

Reuters
·
Mar 26

BRIEF-Acumen Pharmaceuticals, Inc. FY Income From Operations USD -123.832 Million Vs. IBES Estimate USD -127.9 Million

Reuters
·
Mar 26

Acumen Pharmaceuticals, Inc. FY Operating Expenses USD 123.832 Million

THOMSON REUTERS
·
Mar 26

Acumen Pharmaceuticals, Inc. FY Net Income USD -121.335 Million VS. Ibes Estimate USD -124.8 Million

THOMSON REUTERS
·
Mar 26

Acumen Pharmaceuticals Inc - Expects Topline Results for Altitude-Ad Phase 2 Study in Late 2026

THOMSON REUTERS
·
Mar 26

Acumen Pharmaceuticals Inc - Targets Ind Filing for Lead Ebd Clinical Candidate in Mid-2027

THOMSON REUTERS
·
Mar 26

Acumen Pharmaceuticals, Inc. FY Basic EPS USD -2

THOMSON REUTERS
·
Mar 26

Press Release: Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Dow Jones
·
Mar 26

U.S. Earnings Preview: Before Market Open March 26

Dow Jones
·
Mar 26

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 25

Acumen Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
Mar 24

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 23

Acumen Pharmaceuticals Inc. to report fourth-quarter and full-year financial results and host conference call

Reuters
·
Mar 20

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

GlobeNewswire
·
Mar 20